Protara's TARA-002 Cell Therapy Achieves 72% Complete Response Rate in BCG-Naïve Bladder Cancer Patients
核心洞察
Protara (搜索)'s TARA-002 cell therapy demonstrated a 72% complete response rate in BCG-naïve non-muscle invasive bladder cancer patients during the Phase II ADVANCED-2 trial.
The therapy maintained durable responses with 69% complete response at six months and 50% at 12 months, while showing favorable tolerability with mostly Grade 1 adverse events.
If approved, TARA-002 would become the first drug to receive regulatory approval for BCG-naïve NMIBC since BCG itself was introduced decades ago.
Protara (搜索)'s lead cell therapy candidate TARA-002 has achieved promising efficacy results in BCG-naïve non-muscle invasive bladder cancer (NMIBC) patients, demonstrating a 72% complete response rate in a Phase II trial that could position the company to address a significant unmet medical need.
Strong Efficacy Signals in Phase II Trial
The open-label ADVANCED-2 study (NCT05951179) enrolled 29 patients with BCG-naïve NMIBC and showed TARA-002 triggered complete responses in 72% of patients at any time during the study. At the critical six-month timepoint, 18 out of 26 evaluable patients (69%) achieved complete response, with durability maintained in 50% of evaluable patients (7 out of 14) at 12 months.
Notably, four of the five patients who did not initially respond to TARA-002 were able to achieve complete response at six months following re-induction therapy, and all four maintained their response after 12 months, suggesting the therapy's potential for retreatment strategies.
Favorable Safety Profile
The cell therapy demonstrated a favorable tolerability profile throughout the study period. The majority of treatment-emergent adverse events (TEAEs) were classified as Grade 1, with no TEAEs rated Grade 3 or higher observed during the study, indicating a manageable safety profile for this patient population.
Mechanism and Regulatory Pathway
TARA-002 acts through the TLR2 (搜索)/NOD2 pathway, which Protara (搜索) claims can activate both innate and adaptive immune pathways within the bladder wall, allowing the therapy to both directly and indirectly kill tumor cells. The company pursued the BCG-naïve patient population after receiving written feedback from the FDA recommending a registrational path forward for TARA-002 in this setting.
Market Impact and Competitive Landscape
The positive results drove Protara (搜索)'s stock value up 9%, from $6.22 at market close on December 2 to $6.80 at close on December 3. GlobalData analysts currently forecast TARA-002 will launch in 2027, generating $62 million in its first year and reaching $452 million by 2031.
If approved, TARA-002 would become the first drug to obtain regulatory approval in the BCG-naïve NMIBC setting since BCG itself was introduced. While targeted therapies like MSD's Keytruda (pembrolizumab) have been approved for BCG-unresponsive patients, no treatments have yet received regulatory approval specifically for BCG-naïve patients.
Broader Development Program
Alongside the ADVANCED-2 study, Protara (搜索) is assessing TARA-002's effectiveness in BCG-unresponsive patients. Interim results from this registrational cohort are expected in Q1 2026, while enrollment of BCG-unresponsive patients is set to finish in H2 2026.
Following the positive Phase II results, CEO Jesse Shefferman stated the New York-based biotech will now work to "finalize a regulatory pathway for TARA-002 in BCG-naïve patients."
Competitive Pipeline
Several other companies are exploring treatments in the BCG-naïve population. enGene is assessing its gene therapy detalimogene voraplasmid in a Phase II study involving both BCG-naïve and unresponsive patients, having already demonstrated a 63% complete response rate in BCG-unresponsive patients.
Johnson & Johnson released data from the Phase III CREST trial combining sasanlimab, a PD-1 (搜索) inhibitor, with BCG as induction therapy in BCG-naïve, high-risk NMIBC patients. The trial met its endpoints, though J&J has not announced regulatory plans for the combination. The company is also comparing Inlexzo (搜索) (gemcitabine hydrochloride) to BCG in the Phase III SunRISe-3 study.
If approved, detalimogene voraplasmid and sasanlimab are expected to generate $435 million and $924 million respectively by 2031, while Inlexzo (搜索) is projected to reach $4.13 billion in the same timeframe.